LOGIN  |  REGISTER
Astria Therapeutics
Recursion

Privia Health to Participate in Upcoming Investor Conferences

May 31, 2023 | Last Trade: US$20.89 0.42 2.05

ARLINGTON, Va., May 31, 2023 (GLOBE NEWSWIRE) --  Privia Health Group, Inc. (Nasdaq: PRVA), today announced that its management team plans to participate in the following investor conferences:

  • Tuesday, June 6th – 9:00 am ET – William Blair Growth Stock Conference
  • Wednesday, June 7th – 1:30 pm ET – Jefferies Healthcare Conference

The live webcast and replay of each event, as well as any accompanying slide presentation, will be available at ir.priviahealth.com/news-and-events/events-and-presentations.

About Privia Health

Privia Health™ is a technology-driven, national physician enablement company that collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual settings. The Privia Platform is led by top industry talent and exceptional physician leadership, and consists of scalable operations and end-to-end, cloud-based technology that reduces unnecessary healthcare costs, achieves better outcomes, and improves the health of patients and the well-being of providers. For more information, visit priviahealth.com.

Contact
Robert Borchert
SVP, Investor & Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it. 
817.783.4841

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page